ArticleNature medicine2020
Liquid biopsy versus tumor biopsy for clinical-trial recruitment.
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Presenting a sham treatment as personalised increases the placebo effect in a randomised controlled trial.eLife · 2023Trial
- State of the Art on Thyroid Cancer Biology and Oncology.Biomedicines · 2026Review
- Advanced Cancer Liquid Biopsy Platform for miRNA Detection in Extracellular Vesicles Using CRISPR/Cas13a and Gold Nanoarrays.ACS nano · 2025Article
- Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary.BMJ case reports · 2025Article
- Mutational profiling using liquid biopsy to guide targeted therapy in patients with metastatic cancer.Scientific reports · 2025Article
- Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.Nature communications · 2025Article
- Microfluidics-based patient-derived disease detection tool for deep learning-assisted precision medicine.Biomicrofluidics · 2024Article
- Liquid Biopsy Instrument for Ultra-Fast and Label-Free Detection of Circulating Tumor Cells.Research (Washington, D.C.) · 2024Article
- Clinical Circulating Tumor DNA Testing for Precision Oncology.Cancer research and treatment · 2023Article
- Extracellular Vesicles as Biomarkers in Head and Neck Squamous Cell Carcinoma: From Diagnosis to Disease-Free Survival.Cancers · 2023Review
- Liquid biopsy: an examination of platelet RNA obtained from head and neck squamous cell carcinoma patients for predictive molecular tumor markers.Exploration of targeted anti-tumor therapy · 2023Article
- Advances in liquid biopsy in neuroblastoma.Fundamental research · 2022Review
- Comparative Analysis of Free-Circulating and Vesicle-Associated Plasma microRNAs of Healthy Controls and Early-Stage Lung Cancer Patients.Pharmaceutics · 2022Article
- Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directions.Frontiers in oncology · 2022Review
- Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer.OncoTargets and therapy · 2022Review
- Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.Frontiers in oncology · 2022Article
- Multi-scale integrative analyses identify THBS2Theranostics · 2022Article
- Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.Seminars in cancer biology · 2021Review
- Review
- Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development.Therapeutic innovation & regulatory science · 2021Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33230339What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.